L-136-2020
Agreement ID
L-136-2020
Lead IC
NCI
Exclusivity
Exclusive
External Party
Intima Bioscience Inc.
Fiscal Year
2020
Territory
Worldwide
Execution Date
Effective Date
Export Date
Technologies
TAB-4023 Improved Personalized Cancer Immunotherapy
TAB-4157 T-Cell Therapy Against Patient-Specific Cancer Mutations
TAB-3917 T-Cell Therapy Against Patient-Specific Cancer Mutations
TAB-4451 Cancer-reactive T cells from Peripheral Blood
TAB-3869 A Rapid Method of Isolating Neoantigen-specific T Cell Receptor Sequences
TAB-4157 T-Cell Therapy Against Patient-Specific Cancer Mutations
TAB-3917 T-Cell Therapy Against Patient-Specific Cancer Mutations
TAB-4451 Cancer-reactive T cells from Peripheral Blood
TAB-3869 A Rapid Method of Isolating Neoantigen-specific T Cell Receptor Sequences